Evidence map›Paper›PMID 27721455›Full record

ReviewCellular & molecular immunology2017

Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Rita Diehl, Fabienne Ferrara, Claudia Müller, Antje Y Dreyer, Damian D McLeod, Stephan Fricke, Johannes Boltze

Abstract readReview
In one paragraph

Review in Cellular & molecular immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Gut microbes · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Animal models for the evaluation of retinal stem cell therapies.Progress in retinal and eye research · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rita DiehlFraunhofer-Institute for Cell Therapy and Immunology, Leipzig 04103, Germany.
Fabienne FerraraFraunhofer-Institute for Cell Therapy and Immunology, Leipzig 04103, Germany.
Claudia MüllerFraunhofer-Institute for Cell Therapy and Immunology, Leipzig 04103, Germany.
Antje Y DreyerFraunhofer-Institute for Cell Therapy and Immunology, Leipzig 04103, Germany.
Damian D McLeodUniversity of Newcastle, Callaghan, NSW 2308, Australia.
Stephan FrickeFraunhofer-Institute for Cell Therapy and Immunology, Leipzig 04103, Germany.
Johannes BoltzeFraunhofer-Institute for Cell Therapy and Immunology, Leipzig 04103, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Almost every experimental treatment strategy using non-autologous cell, tissue or organ transplantation is tested in small and large animal models before clinical translation. Because these strategies require immunosuppression in most cases, immunosuppressive protocols are a key element in transplantation experiments. However, standard immunosuppressive protocols are often applied without detailed knowledge regarding their efficacy within the particular experimental setting and in the chosen model species. Optimization of such protocols is pertinent to the translation of experimental results to human patients and thus warrants further investigation. This review summarizes current knowledge regarding immunosuppressive drug classes as well as their dosages and application regimens with consideration of species-specific drug metabolization and side effects. It also summarizes contemporary knowledge of novel immunomodulatory strategies, such as the use of mesenchymal stem cells or antibodies. Thus, this review is intended to serve as a state-of-the-art compendium for researchers to refine applied experimental immunosuppression and immunomodulation strategies to enhance the predictive value of preclinical transplantation studies.

Indexed as

Immunosuppression TherapyAnimalsBiomedical ResearchHumansImmunomodulationImmunosuppressive AgentsTransplantationImmunosuppressive Agents

Identifiers

PMID27721455
PMCPMC5301156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.